Leaning on its in-house life sciences expertise GV has backed another biotech startup in the UK, co-leading a £20 million ($27.1M) Series A in Oxford University spinout Vaccitech, which is developing a universal flu vaccine. Oxford University spinout Vaccitech raised £20m ($27m) through series A funding from GV and Sequoia China, along with existing investor Oxford Sciences Innovation and Neptune Ventures. The funds will enable Vaccitech to expand its business, develop its lab structure and push its products, including a universal influenza vaccine and a prostate cancer therapeutic in development. “Vaccine development is an exciting new frontier for the pharmaceutical industry,” said Dr. David Heymann, CEO of Cambridge Biosciences, which has been developing vaccines since 1999.
Oxford University spinout Vaccitech raised £20m ($27m) through series A funding from GV and Sequoia China, along with existing investor Oxford Sciences Innovation and Neptune Ventures. The funds will enable Vaccitech to expand its business, develop its lab structure and push its products, including a universal influenza vaccine and a prostate cancer therapeutic in development. “Vaccine development is an exciting new frontier for the pharmaceutical industry,” said Dr. David Heymann, CEO of Cambridge Biosciences, which has been developing vaccines since 1999.